From Evan Harris <[email protected]>
Subject What Health-Care Affordability Crisis?
Date April 27, 2021 8:59 PM
  Links have been removed from this email. Learn more in the FAQ.
  Links have been removed from this email. Learn more in the FAQ.
PRI's Focus on Health Care

View this email in your browser ([link removed])

What Health-Care Affordability Crisis?

The National Review | Sally C. Pipes
April 25, 2021

Despite the pandemic, between February 2020 and February 2021, U.S. household income rose 13 percent, according to the Commerce Department. Again, that extra income did not go to health care. In fact, consumer spending on health care remained down year-on-year as recently as January.
Read more. . . ([link removed])

Dr. Henry Miller – A COVID-19 Update and Progress on Vaccinations

PRI's Next Round Podcast | Dr. Henry Miller
April 27, 2021

This week’s guest is Dr. Henry Miller, PRI senior fellow in health care studies. In addition to being a physician, Dr. Miller was a former official at the FDA and founding director of the FDA’s Office of Biotechnology. Dr. Miller provides an update on the pandemic, the progress of vaccine distribution, and his perspective on the CDC’s pause on the use of the Johnson & Johnson vaccine. Co-hosts Rowena and Tim discuss Biden’s first 100 days, the recall effort, and new gubernatorial candidate Caitlyn Jenner.

Listen here. . . ([link removed])

Here They Go Again: The Democratic Obsession with Drug Price Controls Will Harm Patients and Diminish Innovation

PRI's Right By the Bay Blog | Wayne Winegarden
April 26, 2021

An analysis by the Congressional Budget Office (CBO) came to a similar conclusion. The CBO estimated that reference pricing could reduce drug industry revenues by up to $1 trillion over 10 years. Drug companies devote about 20 percent of their revenues to R&D, which indicates that any reference pricing scheme would shortchange R&D by hundreds of billions of dollars over the next decade.

Read more. . . ([link removed])

Europe Negotiates A Poor Vaccine Rollout

Forbes.com | Sally C. Pipes
April 26, 2021

Months before regulators approved the vaccines, most developed countries struck deals with manufacturers to order hundreds of millions of doses. The EU did secure lower prices. It’s paying $15 to $19 per dose for the Pfizer-BioNTech vaccine—less than the $20 a dose the United States agreed to pay.

Read more. . . ([link removed])

============================================================
** ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
Copyright © 2021 *Pacific Research Institute*, All rights reserved.
You are receiving this email because you opted in via our website.

Our mailing address is:
101 Montgomery Street, Suite 1300, San Francisco, CA 94104

Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.
Screenshot of the email generated on import

Message Analysis